Sangamo BioSciences | SGMO - Прибыль до налогообложения





Прибыль до налогообложения Изменить Дата
Alaunos Therapeutics USD -7.84M 633K 2023-12
Alnylam Pharmaceuticals USD 221.65M 60.52M 2026-03
Alterity Therapeutics Limited AUD -4.74M 3.53M 2024-12
Amgen USD 1.51B 2.41B 2025-12
Bayer EUR -1.16B 735M 2025-09
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Biogen USD 377.7M 433.7M 2026-03
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Cipla INR 11.69B 6.85B 2025-12
Clal Biotechnology ILS 86.82M 17.9M 2022-12
Compugen USD 56.84M 63.78M 2025-12
CSL USD 2.61B 1.21B 2025-12
Gilead Sciences USD 2.08B 1.56B 2025-12
GlaxoSmithKline GBP 2.14B 919M 2026-03
Grifols EUR 257.85M 190.87M 2024-12
Ionis Pharmaceuticals USD -93M 135M 2026-03
J&J USD 7.82B 2.86B 2026-03
Karyopharm Therapeutics USD -39.9M 9.01M 2025-12
Merck USD 3.42B 3.32B 2025-12
Novartis USD 3.84B 802M 2026-03
Omeros USD -65.12M 21.27M 2024-06
Pfizer USD 5.18B 6.82B 2026-03
Roche Holding CHF 4.79B 3.01B 2025-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sanofi EUR -1.16B 5.5B 2025-12
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
Tectonic Therapeutic USD -18.97M 63K 2025-12
Ultragenyx Pharmaceutical USD -184M 56M 2026-03
Vertex Pharmaceuticals USD 1.33B 32.2M 2025-12